TLC-ART Program

February 22, 2022

TLC-ART Lab Update on HIV Therapies at LEAP Conference

LEAP Logo

Seattle, WA (Feb 12, 2022)–Earlier this month, Dr. Rodney Ho presented updates on the TLC-ART program’s Unitaid funded Global Long-Acting Drug Development (GLAD) Project at the LEAP (Lon-Acting/Extended Release Antiretroviral Research Resource Program) annual meeting.

As part of this meeting, Dr. Ho lectured on the progress of the GLAD project in transforming the current best-of-class oral daily 3-drug pill (Tenofovir, Lamivudine, and Dolutegravir) into a long-acting injectable therapy that can improve patient adherence and provide a higher quality of life for People Living with HIV (PLHIV) globally.

See the full lecture here.

For the complete set of presentations, see the agenda here.